Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 62 Publications

10 Customer Reviews

  • Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NGXSeHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTlO|IhcA>? NGXmNoNFVVOR NUPGOJBCUUN3ME2wMlAxODB5IN88US=> NI\ST4YyPzl3NkC4NC=>
K562 Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnPRllZPzJiaB?= MWfEUXNQ NIfr[3VKSzVyPUCuNFAyKM7:TR?= MmDYNVc6PTZyOEC=
M07e NE\lU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYGyW5h1PzJiaB?= NI[1T4NFVVOR NXLPSmNNUUN3ME2wMlAxOTJizszN NWTRU4V7OTd7NU[wPFA>
ALL3 NYP5bJpIS3m2b4TvfIlkKEG|c3H5 NY\i[ZJWOC5zzszN NUHJZZdEPzJiaB?= M1W1WGROW09? NXTaVFlYUUN3ME2wMlAxODRizszN MkTFNVk5QDl3NEC=
CML M4f6fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjWNlAhdWmw M3r2N2ROW09? MmfuTWM2OD1yLkCwNUDPxE1? NH;1W3cyQTJzOUCxOi=>
BA/F3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHS1UHI4OiCq MULEUXNQ NWXXZ5V3UUN3ME22MlU5QSEQvF2= M1r2SFI{ODh6NkS0
BA/F3 NEfGelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUK3NkBp Ml\oSG1UVw>? MUnJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDCZ5IuSWKuIF2zOVFVKG23dHHueEB4cXSqIFnDOVAhd2ZiMD6wNFA5O87:TR?= MWKyN|A5QDZ2NB?=
BA/F3 NYi2[G9jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDsWHMyPzJiaB?= MkW3SG1UVw>? M2HZdWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJJdqdGRidInw[UBD[3JvQXLsJJdqfGhiSVO1NEBw\iByLkCwOFXPxE1? NE\V[IkzOzB6OE[0OC=>
BA/F3 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PoZlczKGh? NYfTT25rTE2VTx?= NUHFZnNDUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBVOzF3STDteZRidnRid3n0bEBKSzVyIH;mJFEvPzF2zszN MlflNlMxQDh4NES=
BA/F3 MoiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK3NkBp Mn;GSG1UVw>? NV7GXmlWUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiRkS4OnMhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxODoQvF2= MkPmNlM{ODF5MEO=
BA/F3 NFn4NHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETPfJo4OiCq M1rrd2ROW09? M3vYcmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP M2\TeFI{OzBzN{Cz
BA/F3 M3HZN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUO3NkBp MXjEUXNQ NHjBXJlKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCJMkWwSUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA2Oc7:TR?= NU\DRVM{OjN|MEG3NFM>
BA/F3 M33OW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4Lt[VczKGh? NVvsPFk{TE2VTx?= NXm4SJByUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= M1WydlI{OzBzN{Cz
BA/F3 NGLZdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVH2U2FiPzJiaB?= NITZUG9FVVOR M{KzNWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP NGHkXowzOzNyMUewNy=>
BA/F3 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFH3Uos4OiCq MlfHSG1UVw>? M3T3VWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO NUi5b4E6OjN|MEG3NFM>
BA/F3 M4DiUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3NkBp M3LuSmROW09? MVXJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? M4n1XFI{OzBzN{Cz
BA/F3 Mm\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLoU5Q4OiCq MYHEUXNQ NYT4emtPUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiVEOxOWkhdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCzMlbPxE1? NFO2[Y0zOzNyMUewNy=>
BA/F3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLhPVc4OiCq NFfpd3NFVVOR NHfpfHRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCLbnjpZol1cW:wIIfpeIghUUN3MDDv[kAzNjYQvF2= NEjWTYozOzNyMUewNy=>
T cell NUjLSHlxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvvUoI4OiCq M33tXmROW09? MmjBTY5pcWKrdIOgZY51cSCFREOtJIFv\CCjboTpJGNFOjhvaX7keYNm\CCWIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5yMEROwG0> Mlf5NVcyPTR3MUK=
WiDr M3\6Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofLO|IhcA>? NYSxUYg5TE2VTx?= NIrLUGhKSzVyPUCuNFUzKM7:TR?= NUT2[VBCOTV4MUW1NVI>
PC3 M4DEXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\NdGtoPzJiaB?= NHT3bHNFVVOR NVTxflVEUUN3ME2wMlAxQTRizszN NEixOmIyPTZzNUWxNi=>
MDA-MB-231 NXWzSo5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\tZoM4OiCq MliwSG1UVw>? MYDJR|UxRTBwMEGyJO69VQ>? NHXFTXkyPTZzNUWxNi=>
Hs578T Moi3R5l1d3SxeHnjJGF{e2G7 M1jVZlczKGh? NXnpXnhpTE2VTx?= Mm\JS2k2OD1yLkCzJO69VQ>? M2r1XVI1ODF3M{K3
HMEC MUTDfZRwfG:6aXOgRZN{[Xl? M{W2dVczKGh? M2rM[GROW09? M{fDfmdKPTB;MT64JO69VQ>? MXuyOFAyPTN{Nx?=
DU145 MnHCR5l1d3SxeHnjJGF{e2G7 MVi3NkBp NYfQV5FFTE2VTx?= NEDnbW9IUTVyPUCuNVYh|ryP MkHONlQxOTV|Mke=
U251 MVzDfZRwfG:6aXOgRZN{[Xl? MWG3NkBp MUnEUXNQ NUfXe4I{T0l3ME2yMlgyKM7:TR?= M{DlU|I1ODF3M{K3
NCI60 Mki1R5l1d3SxeHnjJGF{e2G7 MVe3NkBp MlqzSG1UVw>? M{jpfGdKPTB;NT63JO69VQ>? MlHjNlQxOTV|Mke=
MALME-3M NV\1Wm1WS3m2b4TvfIlkKEG|c3H5 MXe3NkBp MXLEUXNQ NGXZbINIUTVyPU[uOlEh|ryP MlrmNlQxOTV|Mke=
KM12 MUfDfZRwfG:6aXOgRZN{[Xl? NWfzcII3PzJiaB?= M{XWN2ROW09? M37rNmdKPTB;Nz60OEDPxE1? NGfRb|YzPDBzNUOyOy=>
SW620 NE\TSXNEgXSxdH;4bYMhSXO|YYm= Mn64O|IhcA>? MVfEUXNQ MlL1S2k2OD16LkSzJO69VQ>? MVGyOFAyPTN{Nx?=
RXF 393NL M37oUWN6fG:2b4jpZ{BCe3OjeR?= MVu0JIRigXN? M4K5fGROW09? MU\JR|UxRTBwMEKxO{DPxE1? NH7a[VgzOzJ3M{C3OC=>
LXFA 983L NYHsU|M6S3m2b4TvfIlkKEG|c3H5 MWC0JIRigXN? NUTUbYNtTE2VTx?= NXrzcZljUUN3ME2wMlA2PjVizszN MVeyN|I2OzB5NB?=
PRXF DU145 NFvHTGxEgXSxdH;4bYMhSXO|YYm= MV[0JIRigXN? MXvEUXNQ NF3mZYlKSzVyPUCuNFYzOyEQvF2= M2rPdlI{OjV|MEe0
PAXF 1657L M17mSGN6fG:2b4jpZ{BCe3OjeR?= M4DrT|Qh\GG7cx?= M1[2dGROW09? NXnXT5l1UUN3ME2wMlEzOSEQvF2= MV:yN|I2OzB5NB?=
CXF 1103L NEW2boREgXSxdH;4bYMhSXO|YYm= NXjUZ4RFPCCmYYnz NGXySYdFVVOR NGXXU4FKSzVyPUSuN|Yh|ryP MkLaNlMzPTNyN{S=
GXF251L NGKyfFZEgXSxdH;4bYMhSXO|YYm= NU\1bm9bPCCmYYnz NIjuNlFFVVOR M33SemlEPTB;Mj6yOUDPxE1? NUX1NWZ1OjN{NUOwO|Q>
NCI-H23 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX[3NkBp MX;EUXNQ MVzJR|UxRTJwMkeg{txO M{\FXVI{PTJzMEKw
HCT116 NYSyfJJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z2UFczKGh? NEfjXZhFVVOR MY\JR|UxRTJwMzFOwG0> NVTSZ4k3OjN3MkGwNlA>
MCF7 Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLDO|IhcA>? NIGxUplFVVOR MkPLTWM2OD1{LkW3JO69VQ>? M1rvSlI{PTJzMEKw
NCI-H460 M1:5bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHf2UVk4OiCq MUPEUXNQ NXLIe|JqUUN3ME24Mlk6KM7:TR?= M1fYVVI{PTJzMEKw
DLD1 MoHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTDO|IhcA>? MX7EUXNQ MmLXTWM2OD12Lk[g{txO NFmxVYEzOzV4N{m2NC=>
NCI-H661 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkmyO|IhcA>? NGLGb4dFVVOR NV[2cVd7UUN3ME23Mlgh|ryP MmLVNlM2Pjd7NkC=
A549 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmT6O|IhcA>? NFPubY5FVVOR MUHJR|UxRThwMjFOwG0> MnzzNlM2Pjd7NkC=
U937 NYTEeFc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jnNFczKGh? Mkm5SG1UVw>? M2DJdGlEPTB;MUKuNkDPxE1? NWrRV3BFOjN3Nke5OlA>
HEK293 M3;0OmZ2dmO2aX;uJGF{e2G7 MXGxNOKh|ryP M1;QPWROW09? NV[4SldKUW6mdXPld{BjcW6maX7nJIFn\mmwaYT5JJRwKGi3bXHuJIZ2dGxvbHXu[5RpKEircz30ZYdo\WRiTYn0NUBscW6jc3Wg[ZhxemW|c3XkJIlvKEiHS{K5N{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yNkROwG0> NGjpTZAzOjd5ME[xNC=>
HUVEC NE\M[VZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;k[3cxNjF3wrFOwG0> MX63NkBp MnPKSG1UVw>? MUDJcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKGOnbHyg[5Jwf3SqIHH0JFAvOTVidV2= M4LYW|IzQDV|OUmz
HUVEC NXjKR5pHTnWwY4Tpc44hSXO|YYm= NXL3XVBWOTYEoN88US=> NGXSSFE4OiCq NHnTTGVFVVOR MW\JcoR2[2W|IHHueIlidmerb3flcolkKGGldHn2bZR6KGmwIFjVWmVEKGOxLXP1cJR2emWmIIfpeIghfmG|Y4XsZZIhe22xb4ToJI12e2OuZTDj[YxteyCjc4Pld5Nm\CCjczDJcohq[mm2aX;uJI9nKG6ndIfvdosh\m:{bXH0bY9vKGG2IEGuPEB1dyBzNTD1US=> M362UVIzQDV|OUmz
Plasmodium falciparum M1TVTmZ2dmO2aX;uJGF{e2G7 MUmxNOKh|ryP NUjkUJI4OTVibXnu Mnr0SG1UVw>? NFnLZpZKdmirYnn0d{BRdGG|bX;kbZVuKG[jbHPpdIFzfW1icILvcIln\XKjdHnvckBjgSCrbnjpZol1cW6pIITo[UBHfW6ldHnvckBw\iCSZlPEVGsyKHC{b4TlbY4hf2m2aDDJR|UxKG:oIEGuNVfPxE1? MXeyOFU2ODN|MB?=
PC3 MWrGeY5kfGmxbjDBd5NigQ>? MoL4NE4yKM7:TR?= MkDXOUBp NXP5S5VsTE2VTx?= M4rlcmlvcGmkaYTzJIh2dWGwIGDDN{Bk\WyuIHHkbIV{cW:wIHH0JFExOCCwTR?= NGrvRmsyQTR4Mkm3OS=>
DU145 NHLvZ5NHfW6ldHnvckBCe3OjeR?= M1vnWFAvOSEQvF2= MnK5OUBp MXzEUXNQ MojyTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= NHjLSWIyQTR4Mkm3OS=>
PC3 MX;LbY5ie2ViQYPzZZk> NX;rWYtXOC5zIN88US=> MoDvOUBp NVvJWmtzTE2VTx?= MYfJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgV5JkKFl2MU[gcIV3\WxiYYSgNVAxKG6P MoLBNVk1PjJ7N{W=
DU145 MX3LbY5ie2ViQYPzZZk> M{HIelAvOSEQvF2= NYD4UGhxPSCq MXvEUXNQ M17lc2lvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> MnjJNVk1PjJ7N{W=
PC3 NEP4eWFMcW6jc3WgRZN{[Xl? M4Dhb|AvOSEQvF2= M4XhbVUhcA>? MoHjSG1UVw>? NY[y[2x1UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P Mnr5NVk1PjJ7N{W=
DU145 MWPLbY5ie2ViQYPzZZk> NGn1OooxNjFizszN NEHSelA2KGh? M1LGSWROW09? NEX5PXJKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCIQVugXVU4Pi:\NUe3JIxmfmWuIHH0JFExOCCwTR?= MVOxPVQ3Ojl5NR?=
Huh7 MVHBcpRqfmm{YXygRZN{[Xl? MXGyMlUh|ryP Mlf5OEBl[Xm| MYXEUXNQ NVvtd3EyUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCqdX3hckBJfWh5IHPlcIx{KGG|c3Xzd4VlKGG|IHHjZ5VufWyjdHnvckBw\iC4aYLhcEBmdn[nbH;w[UBxem:2ZXnuJJdqfGirbjDw[ZJqdnWlbHXhdkBz\Werb36gZZQhOi53IIXN NX3pbVRSOTd|NkC2O|Y>
C6/36 NWL5UmJ1SW62aY\pdoFtKEG|c3H5 M4fneVIvPSEQvF2= MUi0JIRigXN? NYHW[ndwTE2VTx?= Mo\vTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBie2mjbjD0bYdmeiCvb4PxeYl1dyCFNj:zOkBk\WyuczDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25ib3[geolz[WxiZX72[YxweGVicILveIVqdiC5aYTobY4heGW{aX71Z4xm[XJicnXnbY9vKGG2IEKuOUB2VQ>? MkLZNVc{PjB4N{[=
U937 MmXBSpVv[3Srb36gRZN{[Xl? M2jWTVEh|ryP MVWxJIg> MYPEUXNQ MkHtVoVlfWOnczDiZZNidCCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? NV25WldPOTd4OESwPVk>
U937 Mlv2SpVv[3Srb36gRZN{[Xl? NWqwcVJIOSEQvF2= MVmxJIg> MWXEUXNQ M3fQVXJm\HWlZYOgUHBUNWmwZIXj[YQhXE6IYXzwbIEhemWuZXHz[UBqdiCqdX3hckBWQTN5IHPlcIx{ MX6xO|Y5PDB7OR?=
murine mast cell NV[yWZgxTnWwY4Tpc44hSXO|YYm= NFXkcIIyKM7:TR?= NIDqc5AzPCCq M2nwcGROW09? MWXJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? NWXFNVVnOTd4OESwPVk>
BV-173 M3HjSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnqxTWM2OD1yLkCwNFAxODFyOTFOwG0> M3O3WHNCVkeHUh?=
K-562 M33Ub2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTBwMECwNFAxOjZ4IN88US=> NIHlWWxUSU6JRWK=
BL-70 M2n1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPhVnZEUUN3ME2wMlAxODByMEiyNkDPxE1? M1LCNXNCVkeHUh?=
EM-2 NVzGPYhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHW3OXNKSzVyPUCuNFAxODBzMEig{txO MmnHV2FPT0WU
LAMA-84 M3fGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMECwNFA{OjFizszN MXLTRW5ITVJ?
MEG-01 MlXTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\qZWZFUUN3ME2wMlAxODByOUig{txO MXfTRW5ITVJ?
EoL-1-cell MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLsN2JzUUN3ME2wMlAxODBzM{Gg{txO NYD2b4s2W0GQR1XS
CTV-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwMECwNFQxPCEQvF2= NFK2VXNUSU6JRWK=
TE-15 NEHNW3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\5fnVCUUN3ME2wMlAxPTh7IN88US=> MnHEV2FPT0WU
NOS-1 NWS1TY5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwMEC2NVMh|ryP M1XYPXNCVkeHUh?=
D-336MG NGXiV4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMEC2N{DPxE1? MYXTRW5ITVJ?
LB1047-RCC NF\4ToxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPRWHYyUUN3ME2wMlAxQTh7IN88US=> M{TUT3NCVkeHUh?=
LB996-RCC NITueXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfEeWhKSzVyPUCuNFA6QTFizszN NEfNflRUSU6JRWK=
SW982 NF7MU25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEKxRldKSzVyPUCuNFEyOTVizszN M3fDb3NCVkeHUh?=
TK10 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LBO2lEPTB;MD6wNVE4PCEQvF2= NV\qNo9GW0GQR1XS
A704 MmLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlO4TWM2OD1yLkCxOFkyKM7:TR?= MlTzV2FPT0WU
TE-8 NHLhVFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmH6TWM2OD1yLkCxOVc3KM7:TR?= M1y4cnNCVkeHUh?=
DOHH-2 MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XuV2lEPTB;MD6wNVcyQSEQvF2= M2fLe3NCVkeHUh?=
HOP-62 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVm0cFJ4UUN3ME2wMlAyQDN2IN88US=> M1zjZXNCVkeHUh?=
TE-12 M2nhfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HsXWlEPTB;MD6wNVg3OSEQvF2= NYj6fnZxW0GQR1XS
KGN M1vycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVu5WIJOUUN3ME2wMlAyQTR{IN88US=> NUL6ZlVzW0GQR1XS
NCI-H1648 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XjfGlEPTB;MD6wNlAyOSEQvF2= MoP4V2FPT0WU
OS-RC-2 Mlm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M163dGlEPTB;MD6wNlA{KM7:TR?= MoLuV2FPT0WU
GB-1 NWDNeHpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHlNolKSzVyPUCuNFIyPTdizszN M1HVbHNCVkeHUh?=
RXF393 Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMEKzOVch|ryP NXflUXN[W0GQR1XS
LC-2-ad M1LRRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIeySm5KSzVyPUCuNFI2QDZizszN NGTvXm1USU6JRWK=
KS-1 M1:zXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTBwMEK3N{DPxE1? NFfkc5dUSU6JRWK=
ETK-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLDTWM2OD1yLkCyPFMzKM7:TR?= M{DGbnNCVkeHUh?=
SW954 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjIe2xpUUN3ME2wMlAzQTJ5IN88US=> NIexN2hUSU6JRWK=
Becker MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTBwMEOwNFMh|ryP M{n3bXNCVkeHUh?=
MZ1-PC M4PFSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\jOW9WUUN3ME2wMlA{OTF7IN88US=> MmTrV2FPT0WU
ES6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYC3c5NMUUN3ME2wMlA{OTl|IN88US=> NWXMbFV3W0GQR1XS
KURAMOCHI NHHC[mVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPYbVllUUN3ME2wMlA{PDh5IN88US=> NF[weXpUSU6JRWK=
CGTH-W-1 NXjKZm9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3P1NmlEPTB;MD6wN|U1QCEQvF2= NWP1fWkyW0GQR1XS
VA-ES-BJ M2LKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\VTWM2OD1yLkCzPVAzKM7:TR?= M3LSWnNCVkeHUh?=
LXF-289 M363Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;vXmlEPTB;MD6wN|k2PiEQvF2= M1;2Z3NCVkeHUh?=
MPP-89 MmeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoWwTWM2OD1yLkC0NFQ6KM7:TR?= MlnBV2FPT0WU
SW872 NXG0SoVQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTBwMESxOlEh|ryP MX3TRW5ITVJ?
SNB75 M36wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HhUWlEPTB;MD6wOFQ{PSEQvF2= MlvaV2FPT0WU
PSN1 NG\nOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zBN2lEPTB;MD6wOFQ4PCEQvF2= M335NXNCVkeHUh?=
LB831-BLC MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3P0WmlEPTB;MD6wOFYxQSEQvF2= NU\CPYtrW0GQR1XS
MFH-ino NEHaVG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTBwMES3NlQh|ryP MVLTRW5ITVJ?
TGBC24TKB MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHv6Z3lKSzVyPUCuNFQ4PjFizszN M2C5c3NCVkeHUh?=
A388 MlPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXXSI9KSzVyPUCuNFUxQTVizszN MlvFV2FPT0WU
BB30-HNC MkjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\2cGlEPTB;MD6wOVQ{PyEQvF2= MlnZV2FPT0WU
GI-ME-N MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHZ[2tKSzVyPUCuNFYyOThizszN MX3TRW5ITVJ?
TGBC1TKB M{fQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTBwME[xOlQh|ryP MnvCV2FPT0WU
TE-10 NH[wO2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTBwME[zOVch|ryP MWXTRW5ITVJ?
A498 M4DT[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDPO3ZKSzVyPUCuNFczQDRizszN NIPOVFVUSU6JRWK=
TE-11 NHruPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NID0U3NKSzVyPUCuNFc5PThizszN NITnc2VUSU6JRWK=
BB65-RCC MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTtTWM2OD1yLkC4NlI4KM7:TR?= NFfLVWhUSU6JRWK=
C2BBe1 MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DrNmlEPTB;MD6wPFMxQCEQvF2= NWm5[XkzW0GQR1XS
NCI-H747 NXPHb493T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTWTWM2OD1yLkC4N|YzKM7:TR?= M2jDb3NCVkeHUh?=
IST-MES1 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\5TWM2OD1yLkC4OVUzKM7:TR?= NFX3cVRUSU6JRWK=
KALS-1 M4DzWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr6SpNyUUN3ME2wMlA6PDlizszN MoPGV2FPT0WU
GCIY M{fxUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzrdmpKSzVyPUCuNFk3PTZizszN MXPTRW5ITVJ?
RL95-2 NEP4VplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTBwMUCzPEDPxE1? MX3TRW5ITVJ?
TE-1 MmW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3rCWWlEPTB;MD6xNFU1KM7:TR?= MXHTRW5ITVJ?
NCI-H1355 MnTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknrTWM2OD1yLkGxNFI5KM7:TR?= NFLRWJRUSU6JRWK=
SW962 NHPHRmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;NbmxLUUN3ME2wMlEyOjl{IN88US=> MX;TRW5ITVJ?
KLE NGnrO5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMUGzNVch|ryP NI\iSYxUSU6JRWK=
MC116 Mm\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7qd4RKSzVyPUCuNVE1OSEQvF2= NW\FfZI{W0GQR1XS
NMC-G1 NWfnU4h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwMUG2NFYh|ryP MnfHV2FPT0WU
KU812 NIf1dIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTBwMUG4PFMh|ryP MnvzV2FPT0WU
COLO-829 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkS2TWM2OD1yLkGyNlE{KM7:TR?= MVzTRW5ITVJ?
NTERA-S-cl-D1 M1jvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fK[mlEPTB;MD6xNlI5OyEQvF2= M{TyUHNCVkeHUh?=
IST-MEL1 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMUO0OUDPxE1? NGqxfYdUSU6JRWK=
MLMA M4DhT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPTVZhVUUN3ME2wMlE1ODN{IN88US=> NI\xelBUSU6JRWK=
LS-123 NU\sOWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMUSwOlQh|ryP Ml:wV2FPT0WU
LB2518-MEL Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTjTWM2OD1yLkG0NVYzKM7:TR?= MoHnV2FPT0WU
NB69 NVK1VZp6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXCN|hKSzVyPUCuNVQ1OzZizszN NXXyb|ZwW0GQR1XS
8-MG-BA MlLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMUW0OVgh|ryP M1TpPHNCVkeHUh?=
K5 Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMU[0PFkh|ryP NFfofHZUSU6JRWK=
KINGS-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmizTWM2OD1yLkG2OlY3KM7:TR?= Ml\hV2FPT0WU
SF268 M4DlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMUe0NFQh|ryP MVLTRW5ITVJ?
PF-382 MmfNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjz[VFKSzVyPUCuNVc3PzhizszN MXHTRW5ITVJ?
SH-4 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwMUi0NVMh|ryP NH24UZNUSU6JRWK=
NALM-6 NH;X[HhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrrN25KSzVyPUCuNVkzQTVizszN NIS0bGtUSU6JRWK=
CP66-MEL NWHxWml5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TVUWlEPTB;MD6xPVU{OSEQvF2= NWG0WnBYW0GQR1XS
697 NWXuWppMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrMclZKSzVyPUCuNVk6QDdizszN NUi3SVVwW0GQR1XS
CP67-MEL MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fCT2lEPTB;MD6yNFQ5QCEQvF2= M4jZWnNCVkeHUh?=
DSH1 NIHGTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;6VmlEPTB;MD6yOFAxOSEQvF2= MWfTRW5ITVJ?
HCE-4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPabIhKSzVyPUCuNlY1OzlizszN M{HV[HNCVkeHUh?=
MZ2-MEL MlH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGH3NGtKSzVyPUCuNlg2OzdizszN M1u3b3NCVkeHUh?=
BL-41 NYLDdldDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMkmxNlMh|ryP M{nWb3NCVkeHUh?=
HUTU-80 NEnnVGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXCTZp{UUN3ME2wMlMyPDJizszN NGDMfmxUSU6JRWK=
LOXIMVI NWfr[HZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEezfGpKSzVyPUCuN|E2ODNizszN MWjTRW5ITVJ?
no-10 M13SVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn:5TWM2OD1yLkOxPVMyKM7:TR?= M2PzUXNCVkeHUh?=
KARPAS-422 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\iTWM2OD1yLkOzPVk4KM7:TR?= MYrTRW5ITVJ?
SW684 NGqxeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTBwM{S5PEDPxE1? Ml3XV2FPT0WU
SF126 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7wOGdrUUN3ME2wMlM2PDFizszN NHHXbIpUSU6JRWK=
D-263MG MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TqOmlEPTB;MD6zOlIzPCEQvF2= NUHwVHpkW0GQR1XS
OVCAR-4 M4m1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCzZW51UUN3ME2wMlM4PDN|IN88US=> MlvkV2FPT0WU
BB49-HNC NXjhcmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW[3TXJEUUN3ME2wMlM5PTl7IN88US=> M3;scnNCVkeHUh?=
ONS-76 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XTRmlEPTB;MD60Nlk2OSEQvF2= MUDTRW5ITVJ?
MZ7-mel NIPIdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{SzVmlEPTB;MD60O|kyOSEQvF2= M1HG[XNCVkeHUh?=
RCC10RGB NWjDRXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XRb2lEPTB;MD60PVEyKM7:TR?= NF3xU|VUSU6JRWK=
BOKU Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID5b3JKSzVyPUCuOFkyOzNizszN M{DyNXNCVkeHUh?=
no-11 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTBwNUCyNlgh|ryP NX;Fc4d{W0GQR1XS
IST-SL2 NFe2dmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUn1epJrUUN3ME2wMlUxOzB{IN88US=> NE\5e49USU6JRWK=
RKO M4K5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTBwNUK5OlYh|ryP M3XGTHNCVkeHUh?=
HT-144 NX:1TYNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPZV4pKSzVyPUCuOVM3ODlizszN MXfTRW5ITVJ?
NCI-H446 NVHUTotGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NInHN4tKSzVyPUCuOlI4PiEQvF2= M4K0fXNCVkeHUh?=
QIMR-WIL NWXK[JpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTBwN{C2Nlkh|ryP M1nvcXNCVkeHUh?=
MHH-PREB-1 M1XnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjsO2RKSzVyPUCuO|Q1PjlizszN NIXSfFRUSU6JRWK=
EW-16 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIjtXWFKSzVyPUCuO|YyPzhizszN MXrTRW5ITVJ?
EW-24 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHOdm9KSzVyPUCuO|gyPjVizszN MU\TRW5ITVJ?
LB373-MEL-D NFv0TodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwOEK1NFgh|ryP NYPhXFVTW0GQR1XS
TE-9 NELVWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXqU21KSzVyPUCuPFc2OzJizszN NF\mOVlUSU6JRWK=
A3-KAW MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHYR49wUUN3ME2wMlk5PDV{IN88US=> M3v1[HNCVkeHUh?=
A101D MlvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHr2TYxKSzVyPUGuNFMxPDNizszN NVuwWpg6W0GQR1XS
OCUB-M MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXroSXZQUUN3ME2xMlA1PDF{IN88US=> NH\RNlRUSU6JRWK=
ES4 M1r3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTFwMEWxOFUh|ryP M4\lRXNCVkeHUh?=
TE-6 M4TuSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mne1TWM2OD1zLkKxNlI3KM7:TR?= M4LpPXNCVkeHUh?=
D-502MG NW\lSodrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXJSXhKSzVyPUGuNlM{PzZizszN MXnTRW5ITVJ?
KNS-42 NX3UWmlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTFwMkS0NVIh|ryP M3fMdXNCVkeHUh?=
SNU-C2B NV\tRo17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDaW3FKSzVyPUGuN|A2QDlizszN NYL1cYJTW0GQR1XS
NCI-H1838 M4LHbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHTEbFFKSzVyPUGuN|A4OzNizszN NFLxTXhUSU6JRWK=
NKM-1 NV3tU3ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37qT2lEPTB;MT6zNFg2QSEQvF2= MXrTRW5ITVJ?
GI-1 M{G5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LXfmlEPTB;MT6zOlIzKM7:TR?= M{LOeHNCVkeHUh?=
NB5 NFT5UFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTFwM{m4Nlch|ryP MmK3V2FPT0WU
CAS-1 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwNEC5PVIh|ryP NVzJOY1sW0GQR1XS
HCE-T MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zZT2lEPTB;MT61OlcyPCEQvF2= NVyzV4U2W0GQR1XS
SBC-1 M3P5dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fiV2lEPTB;MT61O|k5PCEQvF2= NFPlVW1USU6JRWK=
JiyoyeP-2003 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFwN{O0OlYh|ryP MV;TRW5ITVJ?
TE-5 NGLZTmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXjGZ3lyUUN3ME2xMlc6OTN7IN88US=> MmjWV2FPT0WU
CAN M4OwTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvndHNKSzVyPUGuPFIzPTJizszN MnH0V2FPT0WU
SK-UT-1 MojoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJwMU[2PVMh|ryP Mny4V2FPT0WU
JVM-2 M2PuNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfQ[3A4UUN3ME2yMlM3Ojh2IN88US=> NFHFbHpUSU6JRWK=
LB771-HNC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfV[|FkUUN3ME2yMlU4PTVzIN88US=> MoKyV2FPT0WU
NCCIT MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJwOE[2NVYh|ryP NXy1d3VyW0GQR1XS
NCI-H2126 MkT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PTdWlEPTB;Mj64O|U2OiEQvF2= MYXTRW5ITVJ?
Calu-6 NW\McW1vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1y0d2lEPTB;Mz6wOVc1OSEQvF2= MVjTRW5ITVJ?
SK-LMS-1 MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLzTWM2OD1|LkGxPFg3KM7:TR?= NYDn[FI6W0GQR1XS
ARH-77 NH;yN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNwNE[5NVUh|ryP MUHTRW5ITVJ?
NB17 Mn[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\QdJlxUUN3ME2zMlY{QDR5IN88US=> MkDDV2FPT0WU
A253 MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXvU3N3UUN3ME2zMlc{OjR4IN88US=> M2fvZnNCVkeHUh?=
OPM-2 NFvjSZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHOVGNSUUN3ME20MlI4Pjh3IN88US=> NG\zVGhUSU6JRWK=
MV-4-11 M1HJbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2W1c2lEPTB;ND6zOlQ2PCEQvF2= MnfMV2FPT0WU
SR NF;OV2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrFTWM2OD12LkS5PVU1KM7:TR?= M4C4NXNCVkeHUh?=
KG-1 M3LnbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYm1RZp2UUN3ME20MlYxQDR3IN88US=> MYfTRW5ITVJ?
OCI-AML2 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTVwOE[xOVQh|ryP NH7GSJJUSU6JRWK=
D-247MG M4r2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnf0TWM2OD14LkGyOVE6KM7:TR?= NI[1OGZUSU6JRWK=
DJM-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLhTWM2OD14LkS4OVU5KM7:TR?= MoL6V2FPT0WU
RPMI-6666 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPJZYdEUUN3ME23MlI4ODZ5IN88US=> NHrjZY9USU6JRWK=
KARPAS-45 NFfjcIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHC[pBKSzVyPUeuOVE3PzFizszN M3HTe3NCVkeHUh?=
LP-1 NGL6c45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\ueG9KSzVyPUeuOVQ4QDJizszN NYnpTYhLW0GQR1XS
RS4-11 M1PGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrPfIdKSzVyPUeuOlU4QDdizszN MWHTRW5ITVJ?
DU-4475 M4XFTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnKdYFKSzVyPUiuNlE3PTJizszN NF\TdnBUSU6JRWK=
MONO-MAC-6 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPJVGNKSzVyPUiuNlcxPjZizszN MlnBV2FPT0WU
NCI-SNU-16 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRThwNU[xNlgh|ryP NFfTTXNUSU6JRWK=
SJSA-1 NH[yR5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnn2TWM2OD16LkeyPFA2KM7:TR?= NUXXb3A4W0GQR1XS
MMAC-SF M4f4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTUZ3JKSzVyPUiuO|k{ODdizszN MWrTRW5ITVJ?
SK-NEP-1 M1nRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7sTWM2OD16Lki5NVU2KM7:TR?= MYLTRW5ITVJ?
J-RT3-T3-5 MlzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrGfINKSzVyPUiuPVY2OjlizszN NH[xNoFUSU6JRWK=
SKM-1 NEe4VmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TjNmlEPTB;OT6wNVc{PCEQvF2= NHPscWlUSU6JRWK=
LB2241-RCC NUTjO5RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVu4OnVOUUN3ME25MlAzODF{IN88US=> MoLxV2FPT0WU
SIG-M5 Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH;kd5JKSzVyPUmuNFI1QTNizszN Mn3zV2FPT0WU
EVSA-T NX7pbI1KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NULl[ZN5UUN3ME25MlI4Pzl|IN88US=> M3;jNHNCVkeHUh?=
GT3TKB MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\oWWlEPTB;OT6zOVU1PiEQvF2= MVLTRW5ITVJ?
NB6 M4H4OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33Ke2lEPTB;OT65NlI2QSEQvF2= NFzXcXNUSU6JRWK=
EHEB MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFyLkC2OVYh|ryP NFjpXI5USU6JRWK=
HEL Mki2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTFyLkS3O|Yh|ryP M{\iW3NCVkeHUh?=
ALL-PO M3LRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFyLke5N|gh|ryP M{jyT3NCVkeHUh?=
TGW M4PiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTFzLkK4Nlgh|ryP M3jaTHNCVkeHUh?=
BC-3 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTF{LkGxN|gh|ryP NWXZ[3l6W0GQR1XS
IA-LM M1jRPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;MdWpwUUN3ME2xNk41PDR3IN88US=> MmLaV2FPT0WU
UACC-257 NVzrZ|F1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi0TWM2OD1zMj65NVk5KM7:TR?= NULDepVNW0GQR1XS
KP-N-YS MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmK0TWM2OD1zMj65Nlg{KM7:TR?= MmPrV2FPT0WU
Raji MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXqTWM2OD1zMz63OFk4KM7:TR?= NYT6dXZEW0GQR1XS
SF539 M3\Tdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXuSIg1UUN3ME2xN{45PTV5IN88US=> NFn1fYFUSU6JRWK=
DMS-153 M4\uSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnRTWM2OD1zND6wNFI5KM7:TR?= M2C2U3NCVkeHUh?=
L-540 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon2TWM2OD1zNT6wOlczKM7:TR?= M3PIfXNCVkeHUh?=
MN-60 NHLRZWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLlTWM2OD1zNT6xPVc6KM7:TR?= NYi3T2RsW0GQR1XS
RPMI-8866 MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTF5LkS0OVQh|ryP MlT5V2FPT0WU
NCI-H510A NYjBOoJST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTF7LkO5O|Mh|ryP NYS1W3NHW0GQR1XS
NB13 Mn7TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTF7LkS4O|ch|ryP MYHTRW5ITVJ?
HAL-01 NWS3NFVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHz4VJZKSzVyPUG5Mlc2PDNizszN MVXTRW5ITVJ?
NCI-H720 MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXpRYRNUUN3ME2yNE4zPzN|IN88US=> MkfUV2FPT0WU
REH NHnYcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjSeZVKSzVyPUKwMlY{PTdizszN NFjydZhUSU6JRWK=
KNS-81-FD M1fGd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLENJRxUUN3ME2yN{4yPDZizszN MorDV2FPT0WU
HC-1 NFjrbFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjGUVdKSzVyPUK0MlU2PTFizszN MVfTRW5ITVJ?
NCI-H2141 NVG5UGE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvWTWM2OD1{ND63O|U1KM7:TR?= M1jhN3NCVkeHUh?=
MOLT-4 M4rS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7ndopKSzVyPUK2MlY4PTNizszN MY\TRW5ITVJ?
OMC-1 M4LLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2[4UGlEPTB;MkeuNVQzOiEQvF2= MYTTRW5ITVJ?
LC-1F MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVW5SYYxUUN3ME2yO{4{OjR3IN88US=> MnfiV2FPT0WU
NCI-H1304 NX21V3VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Ha[mlEPTB;MkiuNVYzQCEQvF2= MnvzV2FPT0WU
BC-1 MoT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXyTWM2OD1{OD62OVEh|ryP NXLnT5o6W0GQR1XS
NCI-H64 M4WzTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHlTWM2OD1{OT62NlU{KM7:TR?= NGXVcZdUSU6JRWK=
MOLT-16 NFvNR3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1T2SWlEPTB;MkmuOlI6OiEQvF2= NFjPbXdUSU6JRWK=
U-87-MG M1HmbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILEWFdKSzVyPUOwMlc3PiEQvF2= NFLIfI1USU6JRWK=
GAK NIT0Z2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{K0c2lEPTB;M{GuNlY5PiEQvF2= MkDEV2FPT0WU
ES8 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmToTWM2OD1|Mj6xNlUzKM7:TR?= Mli0V2FPT0WU
HCC1599 MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoO3TWM2OD1|Mj6zN|I2KM7:TR?= M4\wOXNCVkeHUh?=
EB-3 NEezPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TvNWlEPTB;M{SuN|EyPyEQvF2= MlvhV2FPT0WU
HCC1187 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPFTWM2OD1|NT64NFUzKM7:TR?= MXvTRW5ITVJ?
SK-PN-DW NGW2clVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULt[XRTUUN3ME2zOk4yQTR|IN88US=> MWPTRW5ITVJ?
JVM-3 M1W3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTN5LkKzN|gh|ryP NIjxd5lUSU6JRWK=
HCC2157 NXHDdIdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWqzPY5LUUN3ME2zO{46QTR4IN88US=> MXnTRW5ITVJ?
A4-Fuk NG[0bo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nO[mlEPTB;M{iuNVAxQSEQvF2= MlH1V2FPT0WU
COR-L279 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jlcGlEPTB;NECuNlg2OSEQvF2= NY\ybJFJW0GQR1XS
DEL NYDxdFk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH[0dndKSzVyPUSxMlkxQDZizszN NHW3UHVUSU6JRWK=
NCI-H1395 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKxcG1KSzVyPUSyMlAyPjNizszN NIHnUW5USU6JRWK=
MHH-NB-11 NIXtRWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz0eohKSzVyPUSzMlA5OThizszN M4X2UHNCVkeHUh?=
NCI-H2107 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HVNmlEPTB;NEOuOFg1PiEQvF2= NXHxVJh3W0GQR1XS
NEC8 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTR2LkOzOkDPxE1? NVzBfnllW0GQR1XS
COLO-684 NXOzOIo{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2D3TWlEPTB;NE[uNlI2QCEQvF2= NW\nfIV5W0GQR1XS
LS-411N M3\weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPXOY1XUUN3ME20PE41PzR6IN88US=> MXjTRW5ITVJ?

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo 4% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01445509 Active, not recruiting Solid Tumors National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 27, 2008 Phase 1
NCT03041701 Not yet recruiting Rhabdomyosarcoma|Rhabdomyosarcoma- Alveolar|Rhabdomyosarcoma-Embryonal National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) January 24, 2017 Phase 1|Phase 2
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT03020030 Not yet recruiting Acute Lymphoblastic Leukemia, Pediatric Dana-Farber Cancer Institute|Baxalta US Inc. January 2017 Phase 3
NCT02744768 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dellAdulto December 2016 Phase 2
NCT02923986 Not yet recruiting Chronic Myelogenous Leukemia, Ph1-Positive Bio-Path Holdings, Inc. November 2016 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID